Public Assessment Report. Decentralised Procedure

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Public Assessment Report. Decentralised Procedure"

Transcription

1 Public Assessment Report Decentralised Procedure PERRIGO PARACETAMOL/GUAIFENESIN/PHENYLEPHRINE HYDROCHLORIDE 500 MG/200 MG/10 MG POWDER FOR ORAL SOLUTION UK Licence No: PL 12063/0118 WRAFTON LABORATORIES LIMITED

2 LAY SUMMARY On 19 th September 2012, the UK granted Wrafton Laboratories Limited a Marketing Authorisation (licence) for Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution. Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution contains: Paracetamol which is a pain reliever (analgesic) and helps reduce your temperature when you have a fever. Guaifenesin which is an expectorant to help loosen phlegm. Phenylephrine which is a decongestant to reduce swelling in the passages of the nose to help you breathe more easily. Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution is used for the short term symptomatic relief of colds and flu including aches and pains, headache, blocked nose and sore throat, chills and fever, and for relief from chesty coughs. No new or unexpected safety concerns arose from this application and it was, therefore, judged that the benefits of taking Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution outweigh the risks; hence a Marketing Authorisation has been granted. 2

3 TABLE OF CONTENTS Module 1: Information about initial procedure Page 4 Module 2: Summary of Product Characteristics Page 5 Module 3: Product Information Leaflets Page 5 Module 4: Labelling Page 6 Module 5: Scientific Discussion Page 10 1 Introduction 2 Quality aspects 3 Non-clinical aspects 4 Clinical aspects 5 Overall conclusions Module 6: Steps taken after initial procedure Page 19 3

4 Module 1 Product Name Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution Type of Application Generic hybrid, Article 10.3 Active Substance Form Strength Marketing Authorisation Holder (MAH) Reference Member State (RMS) Concerned Member State (CMS) Procedure Number Paracetamol Guaifenesin Phenylephrine hydrochloride Powder for oral solution 500 mg Paracetamol 200 mg Guaifenesin 10 mg Phenylephrine hydrochloride Wrafton Laboratories Limited, trading as Perrigo Braunton Devon EX33 2DL United Kingdom United Kingdom (UK) The Czech Republic (CZ), Germany (DE), Hungary (HU), Italy (IT) and Poland (PL) End of Procedure Day 210: 1 st August

5 Modules 2 and 3 Summary of Product Characteristics and Patient Information Leaflet In accordance with Directive 2010/84/EU the Summaries of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website. 5

6 Module 4 Labelling 6

7 7

8 8

9 9

10 Module 5 Scientific discussion during initial procedure I INTRODUCTION Based on the review of the data on quality, safety and efficacy, the Czech Republic, Germany, Hungary, Italy, Poland and the UK considered that the application for Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution could be approved. This product has a general sales licence (GSL) and is indicated for the short term symptomatic relief of colds and flu including aches and pains, headache, blocked nose and sore throat, chills and fever, and for relief from chesty coughs. This application for Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution is submitted as an abridged application according to Article 10(3) of Directive 2001/83/EC, claiming to be a hybrid medicinal product to Beechams All-in-One Liquid (500 mg paracetamol, 200 mg guaifenesin and 10 mg phenylephrine hydrochloride per 5 ml), authorised in the UK to Beechams Group PLC on 19 th October 1994 (PL 00079/0320). Paracetamol [acetaminophen; N-(4-Hydroxyphenyl) acetamide] is a para-aminophenol derivative with analgesic, antipyretic and weak anti-inflammatory properties. It is rapidly absorbed and its pharmacokinetic properties have been extensively studied. Studies confirm the analgesic, antipyretic/anti-inflammatory effects of paracetamol and guaifenesin and phenylephrine hydrochloride are administered in fixed-combination products of this type for their additional pharmacodynamic contribution. Guaifenesin is a well-established constituent in over-the-counter expectorants. Although its mechanism of action is poorly understood, it reduces cough reflex sensitivity as well as aiding the expulsion of respiratory mucus associated with upper respiratory tracts infections. It is rapidly absorbed and its pharmacokinetcs are well established. Phenylephrine is a selective α-adrenergic sympathomimetic and at therapeutic doses has negligible effect on β receptors or of the central nervous system (CNS). It is rapidly absorbed and has a well understood pharmacokinetic profile. No new non-clinical studies were conducted, which is acceptable given that the product contains widely-used, well-known drug substances. No clinical studies have been performed and none are required for this application as the pharmacology of paracetamol, guaifenesin and phenylephrine hydrochloride is well-established. For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites. For manufacturing sites outside the community, the RMS has accepted copies of current GMP Certificates or satisfactory inspection summary reports, close-out letters or exchange of information issued by the inspection services of the competent authorities (or those countries with which the EEA has a Mutual Recognition Agreement for their own territories) as certification that acceptable standards of GMP are in place at those non-community sites. 10

11 II. ABOUT THE PRODUCT Name of the product in the Reference Member State Name(s) of the drug substance (INN) Pharmacotherapeutic classification (ATC code) Pharmaceutical form and strength Reference numbers for the Decentralised Procedure Reference Member State Member States concerned Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution Paracetamol Guaifenesin Phenylephrine hydrochloride Paracetamol combinations excl. psycholeptics (N02BE51) Powder for oral solution 500 mg Paracetamol 200 mg Guaifenesin 10 mg Phenylephrine hydrochloride United Kingdom The Czech Republic (CZ), Germany (DE), Hungary (HU), Italy (IT) and Poland (PL) Marketing Authorisation Number PL 12063/0118 Name and address of the authorisation holder Wrafton Laboratories Limited, trading as Perrigo Braunton Devon EX33 2DL United Kingdom 11

12 III SCIENTIFIC OVERVIEW AND DISCUSSION III.1 QUALITY ASPECTS S. Drug substance Paracetamol INN/Ph.Eur name: Chemical name: Paracetamol N-(4-Hydroxyphenyl) acetamide Structural formula: Molecular formula: C 8 H 9 NO 2 Molecular weight: Appearance: Solubility: Guaifenesin INN/Ph.Eur name: Chemical name: A white, or almost white, crystalline powder Sparingly soluble in water, freely soluble in alcohol and very slightly soluble in methylene chloride. Guaifenesin (2RS) - 3(2-methoxyphenoxy) propane-1,2-diol Structural formula: Molecular formula: C 10 H 14 O 4 Molecular weight: Appearance: Solubility: A white, or almost white, crystalline powder Sparingly soluble in water and soluble in alcohol. 12

13 Phenylephrine hydrochloride INN/Ph.Eur name: Phenylephrine hydrochloride Chemical name: (1R)-1-(3-Hydroxyphenyl)-2-(methylamino) ethanol hydrochloride Structural formula: Molecular formula: C 9 H 14 ClNO 2 Molecular weight: Appearance: Solubility: A white, or almost white, crystalline powder Freely soluble in water and soluble in alcohol. The sources of paracetamol, guaifenesin and phenylephrine hydrochloride comply with the relevant European Pharmacopoeia monographs for paracetamol, guaifenesin and phenylephrine hydrochloride, respectively. The manufacturers of the drug substances hold valid EDQM (European Directorate for the Quality of Medicines and Healthcare) Certificates of Suitability. The quality of the substances is suitably controlled in line with the current edition of the relevant European Pharmacopoeia Monographs. The manufacturing process, control of materials, control of critical steps, validation and process development for paracetamol, guaifenesin and phenylephrine hydrochloride were assessed and approved by the EDQM in relation to the granting of the Certificates of Suitability and are therefore satisfactory. Appropriate specifications with suitable test methods and limits are provided for the drug substances. The methods of testing and limits for impurities and residual solvents for each drug substance are in compliance with current guidelines. Batch analysis data for each drug substance are provided and comply with the proposed specifications. The container closure system and re-test period for paracetamol, guaifenesin and phenylephrine hydrochloride complies with the container closure and re-test period specified on the relevant Certificates of Suitability. 13

14 P. Medicinal Product Other Ingredients Other ingredients consist of pharmaceutical excipients sucrose, citric acid E330, tartaric acid E334, sodium cyclamate E952, sodium citrate E331, acesulfame potassium E950, aspartame E951, powdered menthol flavour, lemon flavour, lemon juice flavour and quinoline yellow E104. With the exception of powdered menthol flavour, lemon flavour, lemon juice flavour and quinoline yellow E104; all excipients comply with their respective European Pharmacopoeia monographs. Powdered menthol flavour, lemon flavour, lemon juice flavour and quinoline yellow E104 all comply with in-house specifications. None of the excipients used contain material of animal or human origin. No genetically modified organisms (GMO) have been used in the preparation of this product. Pharmaceutical Development The objective of the development programme was to produce a safe, efficacious product which would be a dry powder mixture that can be easily and rapidly reconstituted with water containing paracetamol, guaifenesin and phenylephrine hydrochloride that could be considered a hybrid product to Beechams All-in-One Liquid. The quantity of the drug substances is such that one sachet corresponds to 20ml oral solution. The formulation of the finished product was based on the formulation of Max Strength Cold and Flu Relief Sachets, authorised to Wrafton Laboratories Limited on 19 th September 2003 (PL 12063/0034). The applicant has provided a suitable product development section. Valid justifications for the use and amounts of each excipient have been provided. Satisfactory dissolution stability data have been provided. A commitment has been provided to reformulate the product and reduce the amount of the sweetener cyclamate to levels in line with those recommended by the Commission on Dietary Food Additive Intake in the European Union COM(2001) 542. Manufacturing Process A satisfactory batch formula has been provided for the manufacture of the product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated and has shown satisfactory results. Process validation data on commercial-scale batches have been provided and are satisfactory. Finished Product Specification The finished product specification proposed for the product is acceptable. Test methods have been described and have been adequately validated, as appropriate. Batch data have been provided and comply with the release specification. Certificates of Analysis have been provided for any working standards used. Container-Closure System This product is packaged in sachets composed of: i) Low density polyethylene 30 gm -2, aluminium foil 15 micron, low density polyethylene 12 gm -2 and paper 40 gm -2 (outer layer). ii) Surlyn 25 gm -2 (product contact layer a thermoplastic sheet/film)/aluminium foil 15 microns/low density polyethylene 12 gm -2 / paper gm -2 (outer layer). 14

15 Pack sizes are 5 and 10 sachets. Satisfactory specifications and Certificates of Analysis have been provided for all packaging components. All primary product packaging complies with the relevant EU directives and EU legislation regarding contact with food and pharmaceutical use. Stability of the product Stability studies were performed on batches of the finished product in the packaging proposed for marketing and in accordance with current guidelines. These data support a shelf-life of 36 months for the product as packaged and a shelf-life of 1½ hours after reconstitution. This medicinal product does not require any special storage conditions. Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labelling The SmPC, PIL and labelling are pharmaceutically acceptable. The UK approved labelling (text only) are included in module 4 of this report. The requirements (Article 59(3) of Directive 2001/83/EC as amended) for user testing have been adequately met by means of a bridging report to a similar PIL of an already approved product (parent product Multi-action Cough & Cold Capsules, containing the same active ingredients and with comparable leaflet format, layout and style). MAA form The MAA form is pharmaceutically satisfactory. Pharmaceutical Expert Report The pharmaceutical expert report has been written by an appropriately qualified person and is a suitable summary of the pharmaceutical dossier. Conclusion From a quality point of view, it is recommended that a Marketing Autorisation is granted for this application. 15

16 III.2 NON-CLINICAL ASPECTS The pharmacodynamic, pharmacokinetic and toxicological properties of paracetamol, guaifenesin and phenylephrine hydrochloride are well-known. As paracetamol, guaifenesin and phenylephrine hydrochloride are widely used, well-known drug substances, the applicant has not provided any additional studies and none are required. An overview based on literature is therefore appropriate. Non-Clinical Overview The non-clinical overview has been written by an appropriately qualified person and is a suitable summary of the non-clinical aspects of the dossier. Impurities The impurities identified in the drug substance and drug product comply with the levels specified in the European Pharmacopoeia and the limits specified by the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) guidelines. Environmental Risk Assessment A satisfactory justification has been provided for the absence of an Environmental Risk Assessment. Conclusion From a non-clinical point of view, it is recommended that a Marketing Authorisation is granted for this application. 16

17 III.3 CLINICAL ASPECTS Clinical Pharmacology No new pharmacokinetic or pharmacodynamic data were submitted with this application and none were required. The proposed product is a hybrid product of the reference product; a powder for oral solution which has the same qualitative and quantitative composition in terms of the drug substances as the reference product, Beechams All-in-One Liquid. Therefore, as per the Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98 Rev 1/Corr**, a bioequivalence study is not required for this application. Efficacy No new efficacy data were submitted with this application and none were required. Safety No new safety data were submitted with this application and none were required. The Pharmacovigilance System and Risk Management Plan The RMS considers that the pharmacovigilance system as described by the applicant fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. A satisfactory justification has been provided for the absence of a Risk Management Plan. Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labelling The SmPC, PIL and labelling are clinically satisfactory and consistent with those for the reference product, where appropriate. Clinical Expert Report The clinical expert report has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier. MAA form The MAA form is clinically satisfactory. Conclusion From a clinical point of view, it is recommended that a Marketing Authorisation is granted for this application. 17

18 IV OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT QUALITY The important quality characteristics of Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution are well-defined and controlled. The specification and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance. NON-CLINICAL No new non-clinical data were submitted and none are required for an application of this type. CLINICAL The proposed product, Perrigo Paracetamol/Guaifenesin/Phenylephrine hydrochloride 500 mg/200 mg/10 mg powder for oral solution is a hybrid product of Beechams All-in-One Liquid. No new or unexpected safety concerns arise from this application. The SmPC, PIL and labelling are satisfactory and consistent with that for the reference product, where appropriate. RISK-BENEFIT ASSESSMENT The quality of the product is acceptable and no new non-clinical or clinical safety concerns have been identified. Extensive clinical experience with paracetamol, guaifenesin and phenylephrine hydrochloride is considered to have demonstrated the therapeutic value of the compounds. The benefit-risk ratio is, therefore, considered to be positive. 18

19 Module 6 STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY Date submitted Application type Scope Outcome 19

Paracetamol 1000 mg Effervescent Tablets PL 31388/0005

Paracetamol 1000 mg Effervescent Tablets PL 31388/0005 Paracetamol 1000 mg Effervescent Tablets PL 31388/0005 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 12 Summary of Product Characteristics Page

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Decentralised Procedure Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion Procedure No: UK Licence No: PL 24598/0029 Noridem Enterprises Limited LAY SUMMARY On 25 January

More information

DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS

DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Steps taken after authorisation summary Page 12 Summary of

More information

Public Assessment Report. Decentralised Procedure PARACETAMOL 1000 MG TABLETS. Procedure No: UK/H/5004/01/DC. UK Licence No: PL 18866/0060

Public Assessment Report. Decentralised Procedure PARACETAMOL 1000 MG TABLETS. Procedure No: UK/H/5004/01/DC. UK Licence No: PL 18866/0060 Public Assessment Report Decentralised Procedure PARACETAMOL 1000 MG TABLETS Procedure No: UK Licence No: PL 18866/0060 Rockspring Healthcare Ltd LAY SUMMARY On 17 January 2013 the Medicines and Healthcare

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride) UK Licence No: PL 20346/0008 Viridian Pharma Ltd LAY SUMMARY Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride)

More information

PL 17871/0208 UKPAR TABLE OF CONTENTS

PL 17871/0208 UKPAR TABLE OF CONTENTS Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure TELMISARTAN DR REDDY S 20 MG TABLETS TELMISARTAN DR REDDY S 40 MG TABLETS TELMISARTAN DR REDDY S 80 MG TABLETS (telmisartan) Procedure No: UK/H/5034/001-003/DC

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Thorens 10 000 I.U. /ml oral drops, solution Thorens 25 000 I.U. /2.5 ml oral solution Deltius 10 000 I.U. /ml oral drops, solution Deltius 25 000 I.U.

More information

HYDROCORTISONE 10 MG TABLETS

HYDROCORTISONE 10 MG TABLETS HYDROCORTISONE 10 MG TABLETS (Hydrocortisone) PL 20072/0238 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure FOSFOMYCIN 3G GRANULES FOR ORAL SOLUTION Procedure No: UK Licence No: PL 31513/0007 Temapharm Sp. z.o.o. LAY SUMMARY On 17 April 2013, Czech Republic, Estonia,

More information

Public Assessment Report. Decentralised Procedure. Cefadroxil 250 mg/5 ml granules for oral. (Cefadroxil monohydrate)

Public Assessment Report. Decentralised Procedure. Cefadroxil 250 mg/5 ml granules for oral. (Cefadroxil monohydrate) Public Assessment Report Decentralised Procedure Cefadroxil 250 mg/5 ml granules for oral suspension (Cefadroxil monohydrate) UK licence no: PL 34088/0033 Alkaloid-INT d.o.o. 1 Cefadroxil 250 mg/5 ml granules

More information

Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR

Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Summary of Product Characteristics Page 14 Patient

More information

LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride)

LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride) LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES (paracetamol, caffeine and phenylephrine hydrochloride) PL 00063/0529 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Summary of

More information

InVita D3 25,000 IU oral solution PL 24837/0039

InVita D3 25,000 IU oral solution PL 24837/0039 InVita D3 25,000 IU oral solution PL 24837/0039 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Page 12 Summary of Product Characteristics Page 13 Patient

More information

TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR

TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Decentralised Procedure Ibuprofen and phenylephrine hydrochloride 200mg/5mg film-coated tablets Procedure No: UK Licence No: PL 17780/0563 Winthrop Pharmaceuticals UK Limited LAY

More information

Sterilised Water for Injections PL 08801/0057 UKPAR

Sterilised Water for Injections PL 08801/0057 UKPAR Sterilised Water for Injections PL 08801/0057 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Paracetamol 500 mg effervescent tablets Procedure No: UK/H/5662/001-002/DC UK Licence No: PL 36390/0177-0178 Cipla (EU) Limited Lay Summary Paracetamol

More information

STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES

STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES (amylmetacresol, 2,4-dichlorobenzyl alcohol, ascorbic acid and sodium ascorbate) PL 00063/0692 UKPAR TABLE

More information

EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid paraffin 6.0% w/w) PL 19876/0013

EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid paraffin 6.0% w/w) PL 19876/0013 EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid paraffin 6.0% w/w) PL 19876/0013 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken

More information

Public Assessment Report. Decentralised Procedure. Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated. Sildenafil citrate UK/H/4855/001-3/DC

Public Assessment Report. Decentralised Procedure. Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated. Sildenafil citrate UK/H/4855/001-3/DC Public Assessment Report Decentralised Procedure Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated Sildenafil citrate UK licence no: PL 08553/0468-70 DR Reddy s Laboratories (UK) Limited 1 LAY SUMMARY

More information

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken

More information

(paracetamol and caffeine) PL 00071/0659

(paracetamol and caffeine) PL 00071/0659 Paracetamol and Caffeine 500 mg/65 mg Tablets (paracetamol and caffeine) PL 00071/0659 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 14 Steps taken

More information

Nicotine 1 mg Compressed Lozenge Nicotine 2 mg Compressed Lozenge PL 00030/0463-0468

Nicotine 1 mg Compressed Lozenge Nicotine 2 mg Compressed Lozenge PL 00030/0463-0468 Nicotine 1 mg Compressed Lozenge Nicotine 2 mg Compressed Lozenge PL 00030/0463-0468 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of

More information

Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC.

Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC. Public Assessment Report Scientific discussion Paracetamol Orifarm 500 mg film-coated tablets (Paracetamol) DK/H/2271/001/DC 15 October 2014 This module reflects the scientific discussion for the approval

More information

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics

More information

MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS

MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps

More information

MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS

MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Steps taken after authorisation summary

More information

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics

More information

PAROXETINE 20 MG TABLETS PAROXETINE 30 MG TABLETS PL 40378/ UKPAR TABLE OF CONTENTS

PAROXETINE 20 MG TABLETS PAROXETINE 30 MG TABLETS PL 40378/ UKPAR TABLE OF CONTENTS PAROXETINE 20 MG TABLETS PAROXETINE 30 MG TABLETS PL 40378/0101-0102 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Summary of Product Characteristics

More information

CETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS

CETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS CETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary Page

More information

Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS

Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps

More information

CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS

CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 8 Steps taken after authorisation

More information

Public Assessment Report UKPAR. Nurofen Joint & Back Pain Relief 5% Gel Nurofen Muscular Pain Relief Gel Pharmacy Only. Ibuprofen

Public Assessment Report UKPAR. Nurofen Joint & Back Pain Relief 5% Gel Nurofen Muscular Pain Relief Gel Pharmacy Only. Ibuprofen Public Assessment Report UKPAR Nurofen Joint & Back Pain Relief 5% Gel Ibuprofen UK Licence No: Reckitt Benckiser Healthcare (UK) Limited 1 LAY SUMMARY Nurofen Joint & Back Pain Relief 5% Gel (ibuprofen)

More information

Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR

Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for

More information

Public Assessment Report. Decentralised Procedure. Mometasone furoate 50 micrograms/actuation nasal spray, suspension

Public Assessment Report. Decentralised Procedure. Mometasone furoate 50 micrograms/actuation nasal spray, suspension Public Assessment Report Decentralised Procedure Mometasone furoate 50 micrograms/actuation nasal spray, suspension (Mometasone furoate monohydrate) UK/H/5471/01/DC UK licence no: PL 36390/0157 Cipla (EU)

More information

Decentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC

Decentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC Applicant: TEVA Pharma

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure TRIAMCINOLONE HEXACETONIDE 20 MG/ML SUSPENSION FOR INJECTION (triamcinolone hexacetonide) Procedure No: UK Licence No: PL 17509/0061 Intrapharm Laboratories

More information

CANESTEN DUAL ACTION 1% W/W CREAM (PL 00010/0645) UKPAR TABLE OF CONTENTS

CANESTEN DUAL ACTION 1% W/W CREAM (PL 00010/0645) UKPAR TABLE OF CONTENTS CANESTEN DUAL ACTION 1% W/W CREAM (PL 00010/0645) UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary Page

More information

Decentralised Procedure. Public Assessment Report

Decentralised Procedure. Public Assessment Report Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report ben-u-ron direkt Erdbeer/Vanille 250/500 mg Granulat in Beuteln ben-u-ron direkt Cappuccino 500/1000

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure MANEO 100 MG, 150 MG AND 200 MG PROLONGED-RELEASE TABLETS TRAMADOL HYDROCHLORIDE UK/H/4160/001-003/DC UK Licence No: PL 17871/0104-6 JENSON PHARMACEUTICAL

More information

Public Assessment Report UKPAR. Galpharm Nicotine Replace 2 mg and 4 mg Gum. (Nicotine resinate) UK Licence No: PL 12063/

Public Assessment Report UKPAR. Galpharm Nicotine Replace 2 mg and 4 mg Gum. (Nicotine resinate) UK Licence No: PL 12063/ Public Assessment Report UKPAR Galpharm Nicotine Replace 2 mg and 4 mg Gum (Nicotine resinate) UK Licence No: PL 12063/0133-0134 Wrafton Laboratories Limited 1 LAY SUMMARY Galpharm Nicotine Replace 2 mg

More information

RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS

RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Steps taken after authorisation summary

More information

NUTRYELT, concentrate for solution for infusion

NUTRYELT, concentrate for solution for infusion NUTRYELT, concentrate for solution for infusion Public Assessment Report Decentralised Procedure NUTRYELT, concentrate for solution for infusion (zinc gluconate, copper gluconate, manganese gluconate,

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Amlodipine Pfizer 5 mg tablets Amlodipine Pfizer 10 mg tablets Amlodipine Pfizer 5 mg hard capsules Amlodipine Pfizer 10 mg hard capsules Procedure No:

More information

ANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS

ANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS ANASTROZOLE 1 MG FILM-COATED TABLETS (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Linezolid 2 mg/ml solution for infusion Linezolid 600mg film coated tablets Linezolid 100mg/5ml granules for oral suspension Procedure No: UK Licence No:

More information

Public Assessment Report UKPAR. Fluoride 2800 ppm Toothpaste Fluoride 5000 ppm Toothpaste. (Sodium fluoride) UK Licence No: PL 20117/

Public Assessment Report UKPAR. Fluoride 2800 ppm Toothpaste Fluoride 5000 ppm Toothpaste. (Sodium fluoride) UK Licence No: PL 20117/ Public Assessment Report UKPAR Fluoride 2800 ppm Toothpaste Fluoride 5000 ppm Toothpaste (Sodium fluoride) UK Licence No: PL 20117/0239-0240 Morningside Healthcare Limited 1 LAY SUMMARY Fluoride 2800 ppm

More information

Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044

Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044 Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product

More information

Omeprazole 20 mg gastro-resistant tablets PL 14017/0277

Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation

More information

Montelukast 10mg film-coated tablets PL 17907/0474

Montelukast 10mg film-coated tablets PL 17907/0474 Montelukast 10mg film-coated tablets PL 17907/0474 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation Page

More information

Public Assessment Report. Decentralised Procedure. Pemetrexed 25 mg/ml Concentrate for Solution for Infusion. (pemetrexed ditrometamol)

Public Assessment Report. Decentralised Procedure. Pemetrexed 25 mg/ml Concentrate for Solution for Infusion. (pemetrexed ditrometamol) Public Assessment Report Decentralised Procedure Pemetrexed 25 mg/ml Concentrate for Solution for Infusion (pemetrexed ditrometamol) Procedure No: UK Licence No: PL 24668/0187 Caduceus Pharma Ltd 1 LAY

More information

Public Assessment Report. Decentralised Procedure. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution

Public Assessment Report. Decentralised Procedure. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution Public Assessment Report Decentralised Procedure Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution (ipratropium bromide monohydrate) Procedure No: UK Licence No: PL

More information

Public Assessment Report. Decentralised Procedure. Tenofovir Zentiva 245 mg Film-coated Tablets. Tenofovir disoproxil fumarate UK/H/4970/001/DC

Public Assessment Report. Decentralised Procedure. Tenofovir Zentiva 245 mg Film-coated Tablets. Tenofovir disoproxil fumarate UK/H/4970/001/DC Public Assessment Report Decentralised Procedure Tenofovir Zentiva 245 mg Film-coated Tablets Tenofovir disoproxil fumarate UK licence no: PL 17780/0573 Winthrop Pharmaceuticals UK Limited 1 LAY SUMMARY

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Levetiracetam 250 mg film-coated tablets PL 36390/0168; UK/H/5630/001/DC Levetiracetam 500 mg film-coated tablets PL 36390/0169; UK/H/5630/002/DC Levetiracetam

More information

Public Assessment Report UKPAR

Public Assessment Report UKPAR Public Assessment Report UKPAR Amitriptyline 10 mg film-coated tablets Amitriptyline 25 mg film-coated tablets Amitriptyline 50 mg film-coated tablets (Amitriptyline hydrochloride) UK Licence No: PL 17907/0131-133

More information

Public Assessment Report. Decentralised Procedure. CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution

Public Assessment Report. Decentralised Procedure. CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution Public Assessment Report Decentralised Procedure CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution (Macrogol, sodium chloride, sodium hydrogen carbonate

More information

Ascorbic Acid 50 mg Tablets. Ascorbic Acid 100 mg Tablets. Ascorbic Acid 200 mg Tablets. Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287

Ascorbic Acid 50 mg Tablets. Ascorbic Acid 100 mg Tablets. Ascorbic Acid 200 mg Tablets. Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287 Ascorbic Acid 50 mg Tablets Ascorbic Acid 100 mg Tablets Ascorbic Acid 200 mg Tablets Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287 PL 20416/0288 PL 20416/0289 UKPAR TABLE OF CONTENTS Lay Summary

More information

Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules

Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This

More information

PUBLIC ASSESSMENT REPORT Scientific Discussion. ASPROFLASH 500mg, Coated Tablets. Acetylsalicylic acid FR/H/0482/001/DC

PUBLIC ASSESSMENT REPORT Scientific Discussion. ASPROFLASH 500mg, Coated Tablets. Acetylsalicylic acid FR/H/0482/001/DC Direction NEURHO /DP3 Neurologie-Psychiatrie-Antalgie-Rhumatologie- Pneumologie-ORL-Ophtalmologie-Stups et psychotropes PUBLIC ASSESSMENT REPORT Scientific Discussion ASPROFLASH 500mg, Coated Tablets Acetylsalicylic

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure TEMOZOLOMIDE RELIANCE 20 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 100 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 140 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 180

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125

More information

Health Products Regulatory Authority IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE. Scientific discussion

Health Products Regulatory Authority IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE. Scientific discussion IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE Scientific discussion Meropenem 500 mg and 1 g, Powder for Solution for Injection or Infusion (Meropenem Trihydrate)

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Levodopa/Carbidopa/Entacapone Torrent 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Torrent, 75 mg/18.75 mg/200 mg film-coated

More information

Public Assessment Report. Decentralised Procedure. Cefuroxime 250mg and 500mg film-coated tablets. Cefuroxime 500mg film-coated tablets

Public Assessment Report. Decentralised Procedure. Cefuroxime 250mg and 500mg film-coated tablets. Cefuroxime 500mg film-coated tablets Public Assessment Report Decentralised Procedure Cefuroxime 250mg film-coated tablets Cefuroxime 500mg film-coated tablets Procedure No: UK Licence No: PL 35646/0020-0021 Alkem Pharma GmbH 1 LAY SUMMARY

More information

Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178

Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178 Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 11 Steps Taken

More information

Boots Pharmaceuticals Bruise Relief Arnica cream THR 01175/0398 UKPAR TABLE OF CONTENTS. Lay summary Page 2. Scientific discussion Page 3

Boots Pharmaceuticals Bruise Relief Arnica cream THR 01175/0398 UKPAR TABLE OF CONTENTS. Lay summary Page 2. Scientific discussion Page 3 Boots Pharmaceuticals Bruise Relief Arnica cream UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Patient

More information

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient

More information

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o. Public Assessment Report UKPAR Levonorgestrel 1.5 mg tablet (levonorgestrel). UK Licence No: PL 41947/0006 ELC Group s.r.o. 1 LAY SUMMARY Levonorgestrel 1.5 mg tablet (Levonorgestrel, tablet, 1.5 mg) This

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure IMATINIB TEVA UK 100 MG FILM-COATED TABLETS IMATINIB TEVA UK 400 MG FILM-COATED TABLETS (imatinib mesilate) Procedure No: UK Licence No: PL 00289/1516-1517

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure LANSOPRAZOLE 15 MG AND 30 MG ORODISPERSIBLE TABLETS (lansoprazole) Procedure No: UK Licence No: PL 35507/0118-0119 Lupin (Europe) Limited LAY SUMMARY Lansoprazole

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Levodopa/Carbidopa/Entacapone Accord 100 mg/25 mg/200 mg Film-coated tablets Levodopa/Carbidopa/Entacapone Accord 150 mg/37.5 mg/200 mg Film-coated tablets

More information

DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314

DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics

More information

Decentralised Procedure. Public Assessment Report

Decentralised Procedure. Public Assessment Report Decentralised Procedure Public Assessment Report Articainhydrochlorid mit Epinephrin Pierrel 40 mg/ml + 0.01 mg/ml Injektionslösung Articainhydrochlorid mit Epinephrin Pierrel 40 mg/ml + 0.005 mg/ml Injektionslösung

More information

Public Assessment Report UKPAR. Clobetasol Propionate 0.05% w/w Cream Clobetasol Propionate 0.05% w/w Ointment. (Clobetasol propionate).

Public Assessment Report UKPAR. Clobetasol Propionate 0.05% w/w Cream Clobetasol Propionate 0.05% w/w Ointment. (Clobetasol propionate). Public Assessment Report UKPAR Clobetasol Propionate 0.05% w/w Cream Clobetasol Propionate 0.05% w/w Ointment (Clobetasol propionate). UK Licence No: PL 17507/0235-0236 Auden Mckenzie (Pharma Division)

More information

Decentralised Procedure. Public Assessment Report

Decentralised Procedure. Public Assessment Report Doc. Ref: CMDh/208/2005 Rev.5 December 2013 Decentralised Procedure Public Assessment Report Paracetamol Bristol-Myers Squibb 250 / 500 mg mit Erdbeer-/Vanillegeschmack Granulat in Beuteln ; 500 / 1000

More information

Public Assessment Report. Scientific discussion. Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution. Paroxetine (as paroxetine mesilate)

Public Assessment Report. Scientific discussion. Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution. Paroxetine (as paroxetine mesilate) Public Assessment Report Scientific discussion Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution Paroxetine (as paroxetine mesilate) DK/H/0240/002/MR This module reflects the scientific discussion

More information

NEUROTONE THR 00904/0005 UKPAR

NEUROTONE THR 00904/0005 UKPAR NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet

More information

GAVISCON ADVANCE MINT CHEWABLE TABLETS PL 00063/0613 UKPAR TABLE OF CONTENTS

GAVISCON ADVANCE MINT CHEWABLE TABLETS PL 00063/0613 UKPAR TABLE OF CONTENTS GAVISCON ADVANCE MINT CHEWABLE TABLETS PL 00063/0613 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12

More information

Public Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd.

Public Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd. Public Assessment Report UK National Procedure STEXEROL-D 3 1,000 IU FILM-COATED TABLETS STEXEROL-D 3 25,000 IU FILM-COATED TABLETS (colecalciferol) PL 16508/0047 PL 16508/0048 ProStrakan Ltd. 1 LAY SUMMARY

More information

Public Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd

Public Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd Public Assessment Report Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) PL 17901/0254 AstraZeneca UK Ltd 1 LAY SUMMARY Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) This is a

More information

Summary Public Assessment Report. Generics

Summary Public Assessment Report. Generics Summary Public Assessment Report Generics 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public Assessment Report Generics Amoxicillin

More information

Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR

Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Summary of Product Characteristics Page

More information

Summary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy,

Summary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy, Summary Public Assessment Report Generics Amoxicilina + Ácido Clavulânico Ranbaxy 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public

More information

Public Assessment Report. Scientific discussion. Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion

Public Assessment Report. Scientific discussion. Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion Public Assessment Report Scientific discussion Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion (imipenem monohydrate/cilastatin sodium) NL/H/3075/001-002/DC

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion Dropodex 0.1% w/v eye drops, solution (Dexamethasone sodium phosphate) MT/H/0157/001/DC Date: 3 rd May, 2013 This module reflects the scientific discussion

More information

Public Assessment Report. Decentralised Procedure. PAR Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated tabs

Public Assessment Report. Decentralised Procedure. PAR Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated tabs PAR Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated tabs Public Assessment Report Decentralised Procedure Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated

More information

Public Assessment Report Scientific discussion. Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01

Public Assessment Report Scientific discussion. Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01 Public Assessment Report Scientific discussion Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01 This module reflects the scientific discussion for the approval of Hydrokortison CCS. The procedure was

More information

OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES. (omeprazole)

OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES. (omeprazole) OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES (omeprazole) PL 36884/0001, PL 36884/0002, PL 36884/0003, PL 36884/0004, PL 36884/0005 AND PL 36884/0006 UKPAR TABLE OF CONTENTS Lay Summary

More information

Public Assessment Report UK PAR. OxyNorm 50 mg/ml, solution for injection or infusion. (Oxycodone hydrochloride) UK Licence No: PL 16950/0155

Public Assessment Report UK PAR. OxyNorm 50 mg/ml, solution for injection or infusion. (Oxycodone hydrochloride) UK Licence No: PL 16950/0155 Public Assessment Report UK PAR OxyNorm 50 mg/ml, solution for injection or infusion (Oxycodone hydrochloride) UK Licence No: PL 16950/0155 Napp Pharmaceuticals Limited LAY SUMMARY OxyNorm 50 mg/ml, solution

More information

Public Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680

Public Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 Public Assessment Report Scientific discussion Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 This module reflects the scientific discussion for the approval of

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Opticrom Allergy Single Dose 2% w/v Eye Drops, Solution (sodium cromoglicate) Procedure No: UK Licence No: PL 04425/0688 Aventis Pharma Limited (T/A Sanofi-aventis

More information

Public Assessment Report Scientific discussion. Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC

Public Assessment Report Scientific discussion. Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC Public Assessment Report Scientific discussion Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC This module reflects the scientific discussion for the approval of Prednisolon mibe. The procedure

More information

Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498

Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498 Public Assessment Report Scientific discussion Prednisolon Pilum (prednisolone) Asp no: 2013-0498 This module reflects the scientific discussion for the approval of Prednisolon Pilum. The procedure was

More information

Public Assessment Report. UK National Procedure. Perindopril 2 mg Tablets. Perindopril 4 mg Tablets. Perindopril 8 mg Tablets PL 20075/0294-0296

Public Assessment Report. UK National Procedure. Perindopril 2 mg Tablets. Perindopril 4 mg Tablets. Perindopril 8 mg Tablets PL 20075/0294-0296 Public Assessment Report UK National Procedure Perindopril 2 mg Tablets Perindopril 4 mg Tablets Perindopril 8 mg Tablets PL 20075/0294-0296 Accord Healthcare Limited 1 LAY SUMMARY This is a summary of

More information

Weleda Hayfever Relief Oromucosal Spray NR 00298/0275 UKPAR

Weleda Hayfever Relief Oromucosal Spray NR 00298/0275 UKPAR Weleda Hayfever Relief Oromucosal Spray NR 00298/0275 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Summary of Product Characteristics Page

More information

Public Assessment Report

Public Assessment Report Public Assessment Report SoLo Prep PL 11847/0013 MHRA: PAR SoLo Prep PL 11847/0013 1 SOLO PREP PL 11847/0013 UKPAR TABLE OF CONTENTS Page Lay Summary 3 Scientific discussion 4 Steps taken for assessment

More information

Public Assessment Report. Decentralised Procedure. Alimemazine tartrate 7.5mg/5ml Syrup. Alimemazine tartrate 30mg/5ml Syrup

Public Assessment Report. Decentralised Procedure. Alimemazine tartrate 7.5mg/5ml Syrup. Alimemazine tartrate 30mg/5ml Syrup Public Assessment Report Decentralised Procedure Alimemazine tartrate 7.5mg/5ml Syrup Alimemazine tartrate 30mg/5ml Syrup Procedure No: UK Licence No: PL 41830/0029-0030 NRIM Limited 1 LAY SUMMARY Alimemazine

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Decentralised Procedure Alendronic Acid and Calcium/Cholecalciferol 70+1000mg/880IU Film-coated Tablets+Effervescent Tablets Procedure No: UK Licence No: PL 04416/1162-4 Sandoz

More information